Manchester Spinout Raises £1.8m to Treat Chronic Diseases

Northern Gritstone invests in Apini, Manchester spinout – Northern Financial Review

Northern Gritstone, the investment firm focused on science and technology enabled businesses in the North of England, said it has made a £1.8 million commitment to University of Manchester life sciences spinout Apini. Apini is developing a novel small molecule for the treatment of chronic inflammatory diseases. Potential indications include Crohn’s disease and Ulcerative Colitis, the two most common forms of inflammatory bowel disease (IBD), whi…

Manchester spinout raises £1.8m to treat chronic diseases

Apini, a small molecule drug development programme being advanced by Syncona’s accelerator Slingshot Therapeutics, has raised £1.8m to continue its development of treatments for chronic inflammatory diseases. Spun out of the University of Manchester, and supported by the university’s Innovation Factory, the company is developing a novel small molecule for the treatment of diseases including Crohn’s disease and Ulcerative Colitis. The funding com…

Northern Gritstone invests in Manchester spinout Apini

Northern Gritstone, the groundbreaking life sciences and deeptech investment firm, has today announced a commitment to invest £1.8 million into Apini, a small molecule drug development programme being advanced by Syncona’s accelerator Slingshot Therapeutics (“Slingshot”).Apini is a spinout from The University of Manchester developing a new treatment for chronic inflammatory diseases using a small molecule approach. The company was formed with he…